Advanced in SVC Obstruction

Baruch Brenner

39 Jabotinski St, 
Petah Tiqwa, M, IL 
Advanced in SVC Obstruction
39 Jabotinski St, 
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Baruch Brenner practices in Petah Tiqwa, Israel. Mr. Brenner is rated as an Advanced expert by MediFind in the treatment of SVC Obstruction. His top areas of expertise are Colorectal Cancer, SVC Obstruction, Esophageal Cancer, Stomach Cancer, and Bone Marrow Transplant.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of SVC Obstruction.

Gender
Male

Locations

39 Jabotinski St, Petah Tiqwa, M 49100, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Drug: Nivolumab+Ipilimumab
Study Phase: Phase 2
View 1 Less Clinical Trial

85 Total Publications

Methotrexate-induced Reversible Stroke-like Neurotoxicity.
Methotrexate-induced Reversible Stroke-like Neurotoxicity.
Journal: The Israel Medical Association journal : IMAJ
Published: September 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Brenner's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile